<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04841369</url>
  </required_header>
  <id_info>
    <org_study_id>CS-CTP-PCV-III</org_study_id>
    <nct_id>NCT04841369</nct_id>
  </id_info>
  <brief_title>Phase III Clinical Trial of a Candidate PCV13 in Healthy People Aged 6 Weeks and Above (PICTPCV13i)</brief_title>
  <official_title>A Randomized,Blind, Positive-controlled Phase III Clinical Trial to Evaluate the Safety and Immunogencity of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine（CRM197,TT） in Healthy People Aged 6 Weeks and Above</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CanSino Biologics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Henan Center for Disease Control and Prevention</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>CanSino Biologics Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Streptococcus pneumoniae is a major cause of morbidity and mortality in children worldwide,&#xD;
      resulting in up to 1 million pediatric deaths every year.Since the licensure of PCV7 and&#xD;
      PCV13,the reported overall decline in invasive pneumococcal disease in hospitalized children&#xD;
      younger than 5 years several years is approximately 60% in Western countries.This is a single&#xD;
      center,blind, randomized, positive-controlled clinical trial.The purpose of this study is to&#xD;
      preliminary evaluate the safety of PCV13i vaccine in subjects at age of 7 months and&#xD;
      above,and to investigate the safety and immunogenicity of PCV13i vaccine at age of 2 and 3&#xD;
      months,compared to PCV13.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 13, 2021</start_date>
  <completion_date type="Anticipated">April 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of PCV13i in preventing pneumococcal infections</measure>
    <time_frame>Within 7 days post each vaccination</time_frame>
    <description>Occurance of adverse reactions in all subjects</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety of PCV13i in preventing pneumococcal infections</measure>
    <time_frame>Within 30 days post each vaccination</time_frame>
    <description>Occurance of adverse reactions in all subjects</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunogenicity of PCV13i in subjects of 2 months (at least 6 weeks) old (Arm 1A-1B)</measure>
    <time_frame>30 days post three doses</time_frame>
    <description>Serotype-specific seropositivity rates of Immunoglobulin G GMC concentrations above 0.35ug/ml</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunogenicity of PCV13i in subjects of 7 to 11 months old (Arm 4A-4B)</measure>
    <time_frame>30 days post three doses</time_frame>
    <description>Serotype-specific seropositivity rates of Immunoglobulin G GMC concentrations above 0.35ug/ml</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunogenicity of PCV13i in subjects of 12 months to 5 years old (Arm 5A, 5B, 6A, 6B)</measure>
    <time_frame>30 days post last dose of vaccination</time_frame>
    <description>Serotype-specific seropositivity rates of Immunoglobulin G GMC concentrations above 0.35ug/ml</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunogenicity of PCV13i in subjects of age 50 years old and above (Arm 6A, 6B, 7A, 7B)</measure>
    <time_frame>30 days post vaccination</time_frame>
    <description>Serotype-specific seropositivity rates of Immunoglobulin G GMC concentrations above 0.35ug/ml</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immuogenicity in terms of GMT in subjects of 2 months (at least 6 weeks) old (Arm 1A-1B)</measure>
    <time_frame>30 days post three doses</time_frame>
    <description>GMT of serotype-specific OPA antibody with the titer of ≥1:8 ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity in terms of IgG concentration in subjects of 2 months (at least 6 weeks) old (Arm 1A-1B)</measure>
    <time_frame>30 days post three doses</time_frame>
    <description>Serotype-specific Immunoglobulin G with a concentration of ≥1.0μg/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of PCV13i in terms of in subjects of 2 months (at least 6 weeks) old (Arm 1A-1B)</measure>
    <time_frame>6 months post one to three doses of vaccination</time_frame>
    <description>Occurance of SAE in subjects of this age group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immuogenicity in terms of GMT in subjects of 7 to 11 months old (Arm 3A-3B)</measure>
    <time_frame>30 days post two doses</time_frame>
    <description>GMT of serotype-specific OPA antibody with the titer of ≥1:8 ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immuogenicity in terms of GMT in subjects of 12 months to 5 years old (Arm 4A, 4B, 5A, 5B)</measure>
    <time_frame>30 days post last dose of vaccination</time_frame>
    <description>GMT of serotype-specific OPA antibody with the titer of ≥1:8 ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity in terms of IgG concentration in subjects of 7 to 11 months old (Arm 3A-3B)</measure>
    <time_frame>30 days post two doses</time_frame>
    <description>Serotype-specific Immunoglobulin G with a concentration of ≥1.0μg/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity in terms of IgG concentration in subjects of 12 months to 5 years old (Arm 4A, 4B, 5A, 5B)</measure>
    <time_frame>30 days post last dose of vaccination</time_frame>
    <description>Serotype-specific Immunoglobulin G with a concentration of ≥1.0μg/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of PCV13i in terms of SAE in subjects of 7 to 11 months old (Arm 3A-3B)</measure>
    <time_frame>6 months post two doses</time_frame>
    <description>Occurance of SAE in subjects of this age group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of PCV13i in terms of SAE in subjects of 12 months to 5 years old (Arm 4A, 4B, 5A, 5B)</measure>
    <time_frame>6 months post last dose of vaccination</time_frame>
    <description>Occurance of SAE in subjects of this age group</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Anticipated">3420</enrollment>
  <condition>Pneumococcal Infections</condition>
  <condition>Streptococcal Infections</condition>
  <condition>Bacterial Infections</condition>
  <arm_group>
    <arm_group_label>1A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received four doses of PCV13i at 2 months of age (At least 6 weeks old)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects received four doses of PCV13 at 2 months of age (At least 6 weeks old)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received four doses of PCV13i at 3 months of age</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject received three doses of PCV13i at 7 to 11 months of age</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subject received three doses of PCV13 at 7 to 11 months of age</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received two doses of PCV13i at 12 to 23 months of age</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects received two doses of PCV13 at 12 to 23 months of age</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects received one dose of PCV13i at 2 to 5 years old.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects received one dose of PCV13 at 2 to 5 years old.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>13-Valent Pneumococcal Polysaccharide Conjugate Vaccine（CRM197,TT）</intervention_name>
    <description>0.5mL,Intramuscular</description>
    <arm_group_label>1A</arm_group_label>
    <arm_group_label>2A</arm_group_label>
    <arm_group_label>3A</arm_group_label>
    <arm_group_label>4A</arm_group_label>
    <arm_group_label>5A</arm_group_label>
    <other_name>PCV13i</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>13-Valent Pneumococcal Polysaccharide Conjugate Vaccine</intervention_name>
    <description>0.5mL,Intramuscular</description>
    <arm_group_label>1B</arm_group_label>
    <arm_group_label>3B</arm_group_label>
    <arm_group_label>4B</arm_group_label>
    <arm_group_label>5B</arm_group_label>
    <other_name>Prevnar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy subjects of 2 months (minimum 6 weeks), 3 months , 7 months and above;&#xD;
&#xD;
          -  Willing to provide proof of identity;&#xD;
&#xD;
          -  Without vaccination history of pneumococcal vaccine;&#xD;
&#xD;
          -  None-pregnancy or do not plan to pregnancy recently;;&#xD;
&#xD;
          -  Volunteers of 18 years old and above who have the ability to understand clinical&#xD;
             studie progress and sign informed consent;&#xD;
&#xD;
          -  Volunteers of 8-17 years old and their guardians who willing sign informed consent;&#xD;
&#xD;
          -  Able to understand and sign the informed consent by their guardians or trustees for&#xD;
             the volunteers of 8 years old and below;&#xD;
&#xD;
          -  Able and willing comply with the requirements of the protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Volunteers whose axillary body temperature was &gt;37.0# before vaccination&#xD;
&#xD;
          -  Volunteers who suffered from Congenital malformation or developmental disorder,&#xD;
             genetic defect, severe malnutrition, etc;&#xD;
&#xD;
          -  Volunteers who has a history of epilepsy, convulsions or psychosis;&#xD;
&#xD;
          -  Allergic person;&#xD;
&#xD;
          -  Any prior administration of blood products in last 3 month;&#xD;
&#xD;
          -  Any prior administration of other research medicines in last 1 month;&#xD;
&#xD;
          -  Plans to participate in or is participating in any other drug clinical study;&#xD;
&#xD;
          -  Any prior administration of attenuated live vaccine in last 14 days;&#xD;
&#xD;
          -  Any prior administration of subunit or inactivated vaccines in last 7 days;&#xD;
&#xD;
          -  Had fever before vaccination, Volunteers with temperature &gt;37.0°C on axillary setting;&#xD;
&#xD;
          -  According to the investigator's judgement, the subjects have any other factors that&#xD;
             make them unfit to enroll the clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Weeks</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shengli Xia</last_name>
    <role>Principal Investigator</role>
    <affiliation>Henan Province Center for Disease Control and Prevention</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lili Huang</last_name>
    <phone>+8613643826177</phone>
    <email>13643826177@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Neihuang Center for Disease Control and Prevention</name>
      <address>
        <city>Anyang</city>
        <state>Henan</state>
        <zip>450016</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huang Lili</last_name>
      <phone>13643826177</phone>
      <email>13643826177@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 8, 2021</study_first_submitted>
  <study_first_submitted_qc>April 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2021</study_first_posted>
  <last_update_submitted>August 2, 2021</last_update_submitted>
  <last_update_submitted_qc>August 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PCV13</keyword>
  <keyword>13 valent Pneumococcal conjugate vaccine</keyword>
  <keyword>Pneumococcal Infections</keyword>
  <keyword>Safety</keyword>
  <keyword>Immunogenicity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Bacterial Infections</mesh_term>
    <mesh_term>Pneumococcal Infections</mesh_term>
    <mesh_term>Streptococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

